Clinical trials

Clinical trials features

• 

  HIV-positive women in clinical trials: A gap in the facts

  Sharon L Walmsley is one of a group of female physicians, experts and patient advocates who together set up Women for Positive Action, an organisation that campaigns...

  From:  HIV treatment update

• 

  START… and why the time is now

  Simon Collins of HIV i-Base looks at an important and exciting new study of when to start HIV therapy, which needs your help....

  From:  HIV treatment update

• 

  Making sense of randomised trials

  Want to know more about cutting edge treatment news but feeling blinded by science? Caroline Sabin, Professor of Medical Statistics and Epidemiology at University College London, describes...

  From:  HIV treatment update

• 

  HATIP #38, 22nd December 2004

  Combination of antibiotics as effective and safe as co-trimoxazole at preventing infections, but too expensive to use where needed? http://www.aidsmap.com/en/news/3806F479-2DCA-4701-8A30-32C79DEF1E46.asp?hp=1 A combination of the antibiotics atovaquone and...

  From:  HIV & AIDS treatment in practice

Clinical trials in your own words

• 

  Living with HIV and hep C co-infection and haemophilia

  For most people, coping with HIV is enough of a problem in itself, but when you throw in a lifetime disorder such as haemophilia, and...

  From:In your own words

Clinical trials news from aidsmap

• Low-dose stavudine study debated between South African researchers and activists

  A proposed trial of low-dose stavudine (also known as d4T) sparked a heated debate between South African researchers and activists at the opening of the first Southern African HIV Clinicians' Society Conference held in Cape Town last month. Professor ...

  11 December 2012 | Lesley Odendal

• New fixed-dose combination pills measure up to Atripla - corrected version*

  Several studies, or updates of studies, comparing newer against older drug regimens were presented at the Eleventh International Congress on Drug Therapy in HIV Infection last week. Amongst them were the 48-week results from the STAR study, an open-label ...

  20 November 2012 | Gus Cairns

• The research agenda for antiretroviral prevention – now it gets complex

  We now know that starting antiretroviral therapy early, pre-exposure prophylaxis (PrEP) and vaginal microbicides can all have an impact on HIV transmission, Victor de Gruttola told a satellite session at the International AIDS Society conference (IAS 2011) in Rome on Sunday. ...

  18 July 2011 | Roger Pebody

• Protease inhibitor monotherapy in African setting results in viral load, but not CD4, failure in the short term

  A study of protease inhibitor monotherapy in Africa has found that 25% fewer patients on monotherapy achieved an undetectable viral load than those on standard combination therapy. However, CD4 increases were the same in both groups. The study adds ...

  10 November 2010 | Gus Cairns

• Where is HIV vaccine research heading?

  Following last year’s positive result from an HIV vaccine trial in Thailand the Global HIV Vaccine Enterprise has issued a new scientific plan, calling for a speeded-up effort to test new vaccine candidates in large trials. Global HIV Vaccine Enterprise ...

  08 September 2010 | Keith Alcorn

• Imiquimod a good treatment for pre-cancerous anal lesions in men with HIV

  HIV treatment centres should screen and treat pre-cancerous anal lesions, UK investigators argue in the online edition of AIDS. They were prompted to make this suggestion by research showing that treatment with imiquimod cream resolved or downgraded high-grade pre-cancerous anal ...

  02 September 2010 | Michael Carter

• Tenofovir microbicide halves genital herpes infections and appears safe

  One of the most unexpected and exciting results of the CAPRISA trial of a successful microbicide (see aidsmap article: Microbicides can work, CAPRISA trial shows, but more trials needed before approval) was that the gel also reduced ...

  21 July 2010 | Gus Cairns

• Microbicides can work, CAPRISA trial shows, but more trials needed before approval

  “Today is the day we achieve proof of concept for microbicides,” said Professor Gita Ramjee, head of the HIV Research Unit of the South African Medical Research Council. She was opening a session at the Eighteenth International AIDS ...

  20 July 2010 | Gus Cairns

• Maraviroc potentially useful if neurological disease is present

  Maraviroc (Celsentri) may be a good option for patients with advanced HIV disease and neurocognitive impairment, a small observation study published in the online edition of AIDS suggests. Six patients took the CCR5 inhibitor as part ...

  15 July 2010 | Michael Carter

• Myriad halts HIV maturation inhibitor drug programme

  Myriad Pharmaceuticals is to halt its research programme designed to develop an HIV maturation inhibitor, the company announced on June 7th. Maturation is the last stage in the production of HIV before it buds from a human ...

  08 June 2010 | Keith Alcorn

More news

Clinical trials news selected from other sources

• Testing HIV Prevention Tools: Other Ways Up the Alley

  We need to design prevention trials that ask, “Is this test product better than nothing?” rather than, “Is this test product better than the best available prevention combination we have?”

  15 March 2013 | Poz

• Panel Urges NIH to Reduce HIV, Hep C Research on Primates

  The National Institutes of Health (NIH) should reduce its use of chimpanzees for medical research, according to an NIH-commissioned working group.

  06 February 2013 | Poz magazine news

• HIV trial under scrutiny

  A potential breakthrough in the quest to prevent HIV and AIDS has collided with sensitivities about testing expensive drugs in poor parts of the world.

  17 January 2013 | Nature.com

• Industry Funding Changes Study Results, Research Shows

  Drugs and medical devices tend to appear more beneficial in scientific papers if they were manufactured by the company that sponsored the study, showing that who pays for the clinical trial has a direct impact on the reported outcome, according to a new analysis by researchers at UCSF and the Cochrane Collaboration.

  20 December 2012 | University of California press release

• As drug industry’s influence over research grows, so does the potential for bias

  Arguably the most prestigious medical journal in the world, the New England Journal of Medicine regularly features articles over which pharmaceutical companies and their employees can exert significant influence.

  26 November 2012 | Washington Post

• Doctors tread warily over insider trading

  Two years ago US authorities arrested and charged Yves Benhamou, a French doctor, with insider trading linked to passing on his confidential knowledge of clinical trials of Albuferon, a hepatitis drug. That was one of a growing series of criminal investigations in the healthcare sector, many of which start with connections via “expert networks”, essentially companies which convene meetings, for a fee, between investors and medical experts.

  24 November 2012 | Financial Times

• (PrEP) The ANRS-IPERGAY study should be discontinued : prevention research in France is in disarray

  French HIV prevention activist group The Warning has issued a press release saying that the placebo arm of the French IPERGAY randomised controlled study of intermittent PrEP should be dropped. This is in response to a 31 October press release by the French National HIV Research Agency, ANRS, that said it should continue - see http://public.adequatesystems.com/pub/link/203893/034296629555571351674647159-anrs.fr.html . The Warning's position does not reflect the position of other French community organisations, which take positions from support of the IPERGAY trial as it is, to demanding PrEP be made available alongside the trial, to total rejection of it. See http://www.ipergay.fr/Les-avis-des-comites-sur-la-poursuite-de-l-essai-Ipergay_a91.html for a sumary of community reports to the trial co-ordinators (in French).

  09 November 2012 | The Warning

• SOUTH AFRICA: Two women unlock possible key to HIV vaccine

  Two South African women may have helped unlock the key to a vaccine to rid the world of one its deadliest epidemics, according to new research released by South African HIV experts. Because they acquired HIV while taking part in large-scale clinical trials, researchers were able to follow them for years, discovering in the process that their bodies produce rare antibodies found in only one out of every five HIV patients.

  23 October 2012 | IRIN Plus News

• GlaxoSmithKline To Make Clinical Trial Data Available To Other Researchers

  GlaxoSmithKline (GSK) CEO Andrew Witty "said on Thursday detailed data from its clinical trials would be made available to other researchers," Reuters reports, adding, "That would include anonymized patient-level results that sit behind clinical trials of approved and failed drugs"

  15 October 2012 | Kaiser Daily Global Health Policy Report

• Launch of the Good Participatory Practice Guidelines for TB Drug Trials

  The Stakeholder and Community Engagement Workgroup of the Critical Path to TB Drug Regimens initiative launches guidelines that will facilitate the involvement of communities and participants in the conduct of TB drug trials.

  04 October 2012 | Critical Path to TB Drug Regimens

More news